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REVIEW ARTICLE OPEN
Recent advances in the production of recombinant
glycoconjugate vaccines
Emily Kay1, Jon Cuccui1 and Brendan W. Wren 1
Glycoconjugate vaccines against bacteria are one of the success stories of modern medicine and have led to a signiﬁcant reduction
in the global occurrence of bacterial meningitis and pneumonia. Glycoconjugate vaccines are produced by covalently linking a
bacterial polysaccharide (usually capsule, or more recently O-antigen), to a carrier protein. Given the success of glycoconjugate
vaccines, it is surprising that to date only vaccines against Haemophilus inﬂuenzae type b, Neisseria meningitis and Streptococcus
pneumoniae have been fully licenced. This is set to change through the glycoengineering of recombinant vaccines in bacteria, such
as Escherichia coli, that act as mini factories for the production of an inexhaustible and renewable supply of pure vaccine product.
The recombinant process, termed Protein Glycan Coupling Technology (PGCT) or bioconjugation, offers a low-cost option for the
production of pure glycoconjugate vaccines, with the in-built ﬂexibility of adding different glycan/protein combinations for custom
made vaccines. Numerous vaccine candidates have now been made using PGCT, which include those improving existing licenced
vaccines (e.g., pneumococcal), entirely new vaccines for both Gram-positive and Gram-negative bacteria, and (because of the low
production costs) veterinary pathogens. Given the continued threat of antimicrobial resistance and the potential peril of bioterrorist
agents, the production of new glycoconjugate vaccines against old and new bacterial foes is particularly timely. In this review, we
will outline the component parts of bacterial PGCT, including recent advances, the advantages and limitations of the technology,
and future applications and perspectives.
npj Vaccines            (2019) 4:16 ; https://doi.org/10.1038/s41541-019-0110-z
INTRODUCTION
A deﬁning characteristic of a successful vaccine is the ability to
evoke long-lasting protective immunity with minimal side effects.
The most successful human vaccines are often glycoconjugates,
which are combinations of a protein added to a sugar glycan.
Coupling a glycan to a protein results in multiple triggers for the
immune system; creating long-term immunological memory and
increasing vaccine stability. Examples of current glycoconjugate
vaccines1 fully licensed for human use include those for Haemophi-
lus inﬂuenzae type B,2,3 Neisseria meningitidis4 and some Strepto-
coccus pneumoniae5 strains. A major advantage of glycoconjugate
vaccines over many existing vaccines is that they are suitable for
most human populations, including infants and the elderly.6
The global glycoconjugate vaccine market is projected to be
worth approximately US $10 billion by 2020. Glycoconjugate
vaccines are traditionally made by chemical activation of the
polysaccharide at random sites, or at the reducing end,7 followed
by conjugation to a carrier protein. This process requires initial
steps to purify the glycan polysaccharide from the pathogenic
organism, against which the vaccine is targeted, including removal
of contaminating endotoxin, and puriﬁcation of the acceptor
protein from the organism of choice. For most licenced vaccines,
the carrier protein is de-activated Corynebacterium diphtheria toxin
197 (CRM197), which has recently been made available as a cloned
product.8 Overall, production via traditional chemical coupling of
glycoconjugate vaccines is a multistep process and requires several
rounds of puriﬁcation to ensure that the glycoconjugate has been
assembled correctly (Fig. 1). Although existing glycoconjugate
vaccines are safe and effective, they have signiﬁcant shortcomings;
they are prone to batch-to-batch variation, have a reduction in
efﬁcacy over time due to glycan/serotype replacement, and are
expensive to produce. Vaccine cost is a major concern for the
Global Alliance Vaccine Initiative (GAVI) who have funded >143
million pneumococcal childhood immunisations in nearly 60
countries. A signiﬁcant part of this cost for the production of the
13-valent pneumococcal vaccine is due to manufacture with
around 700 quality control tests required prior to sale.9
In recent years, signiﬁcant progress has been made in the
chemical synthesis of glycoconjugate vaccines and the use of
outer membrane vesicles (OMVs) or glycosylated OMVs (gly-
cOMVs) as vaccines.10–12 In the case of glycOMVs, the intrinsic
adjuvant properties of OMVs and the ﬂexibility of lipid A choice
holds promise for the generation of a self-adjuvanting, non-toxic
delivery system for carbohydrate antigens.13,14 Discussions on
these strategies is beyond the scope of this review, which will
focus on the construction and production of recombinant
glycoconjugate vaccines by glycoengineering using Protein
Glycan Coupling Technology (PGCT). For reviews on chemical
approaches to production of glycoconjugate vaccines we refer the
reader to the following articles.15–17
THE EVOLUTION OF BACTERIAL PROTEIN GLYCAN COUPLING
TECHNOLOGY
The original genome sequencing of the human gastrointestinal
pathogen Campylobacter jejuni (strain NCTC 11168) in early 2000
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conﬁrmed that a genetic locus hypothesised to be involved in
general protein glycosylation18 was independent of the lipooli-
gosaccharide and ﬂagellar O-linked glycosylation loci.19 Central to
this region was pglB, which encodes the oligosaccharyltransferase
(OST), termed CjPglB, which was found to have signiﬁcant
sequence similarity to the eukaryotic Stt3p protein, an essential
component of the eukaryotic OST complex.20,21
Functional analyses of the genes within the glycosylation locus
revealed the structure of the substrate glycan and that it is
assembled on the lipid carrier undecaprenyl pyrophosphate (Und-
PP), which is present in the inner membrane.22 Und-PP naturally
functions as an anchor for the scaffold construction of oligosac-
charides and polysaccharides, including O-antigens in Gram-
negative bacteria. The next signiﬁcant step was the demonstration
that CjPglB was also able to transfer a range of polysaccharides,
such as structurally different bacterial O-antigens, to C. jejuni
carrier proteins such as AcrA.23 At about the same time, an
extended glycosylation sequon, D/EXNYS/T, recognised by CjPglB
was identiﬁed. This sequon could be engineered into a ﬂexible
secondary structure within a given carrier protein24 or multiple
sequons could be engineered at either the C- or the N-terminus of
carrier proteins (“glycotags”).25
These fundamental studies into the mechanism and properties
of the C. jejuni N-glycosylation system laid the groundwork for
development of the ﬁrst bacterial glycoengineering system. Key
features of the system are, the ability to transfer a relatively broad
range of sugar substrates, and the targeting of heterologous
proteins for site-speciﬁc glycosylation using a short sequence
motif. Collectively, these studies provided the requisite ingredi-
ents for making customised recombinant glycoconjugate vaccines
by PGCT. However, a drawback is the requirement for the
presence of an acetamido group modiﬁcation on the reducing
end sugar in order for the glycan to be transferred by CjPlgB.
THE COMPONENT PARTS FOR THE PRODUCTION OF
RECOMBINANT GLYCOCONJUGATE VACCINES
PGCT can be divided into three stages summarised in Fig. 2:
Glycan expression
The ﬁrst stage in consideration of the construction of a
recombinant glycoconjugate vaccine is to be able to clone and
express the glycan of interest, which is usually a general
glycosylation locus (e.g., C. jejuni pgl), an O-antigen, or a capsular
polysaccharide. This process has been termed Glycan Expression
Technology (GET), and because of its general importance for the
production of glycoconjugate and glycOMV vaccines, has become
a specialised area of glycoengineering in its own right. In many
instances, the cloning and expression of a glycan is straightfor-
ward, where a speciﬁc gene cluster has all the requisite genetic
information that can be transferred to a suitable host cell for
expression. The glycan locus is usually introduced on a low copy
plasmid to the E. coli host where its expression can be veriﬁed on
the cell surface using speciﬁc antisera or lectins (see examples in
Fig. 3). The reduction in price of DNA synthesis, and the ability to
synthesise large regions of DNA, offers a more rapid approach to
the cloning of polysaccharides.
However, a potentially more convenient approach is to use the
bacteria from which the glycan originated, and to introduce the
carrier protein and coupling enzyme into the native host cell (e.g.,
Salmonella paratyphi A) for recombinant expression.26,27 Another
alternative would be to add in pathways from other more closely
related bacteria for optimum expression; such as using surrogate
Pseudomonas aeruginosa genes to reconstitute a Staphylococcus
aureus capsule in E. coli.28
Carrier protein design and expression
The identiﬁcation and characterisation of the extended glycosyla-
tion sequon (D/EXNYS/T) for CjPglB, along with the advent of DNA
synthesis means glycosylation sites can be readily engineered into
a target carrier protein. Insertion of the sequon within a ﬂexible
region of a target protein results in efﬁcient glycosylation by
PglB,24,29 although the efﬁciency is known to vary depending on
location of the sequon.30 This opened up the possibility that
almost any protein could be modiﬁed to become a carrier for the
target glycan. This initially meant that a given carrier protein’s
structure needed to be known, as inaccessible regions would lead
to reduced glycosylation efﬁciency. However, studies that are
more recent have indicated that the D/EXNYS/T sequon can be
added to the termini of a carrier protein, and that multiple
sequons can be added for the production of a more heavily
glycosylated vaccine.25,31
To date it is remarkable that glycoconjugate vaccines have
relied on just CRM197, tetanus toxoid, and more recently, H.
inﬂuenzae protein D.32,33 It could be argued that there will be a
need for different carriers if multiple glycoconjugate vaccines are
licenced and given to an individual. Using the same carrier for
different glycoconjugate vaccines may result in the immune
response dampening the effect of subsequent vaccination.34,35
The ease of DNA synthesis and the introduction of speciﬁc
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Fig. 1 Traditional chemical conjugation method for the production of glycoconjugate vaccines. Multiple steps are required whereby the O-
antigen must be puriﬁed from the pathogen of interest, detoxiﬁed and subject to chemical activation. In parallel, the protein must also be
puriﬁed and chemically activated before protein and glycan can be conjugated. Following conjugation, further rounds of puriﬁcation are
necessary before vaccine can be administered
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glycosylation sites allows enormous variety in the choice of carrier
protein. Questions can now be answered as to whether any given
carrier protein has a “bystander effect” upon immunisation.
Recent PGCT-derived glycoconjugate vaccines contain both the
glycan and protein from the same pathogen, a so called “double-
hit” approach for vaccination, where the carrier protein could play
a more active immunological role.36 This may be particularly
useful for bacterial species with multiple, diverse glycan structures
where it would be difﬁcult to protect against all glycan variants
(e.g., pneumococcal vaccines). In addition, if the protein carrier
was from another pathogen and had immunological properties in
its own right, then dual protection against two infections may be
possible from a single recombinant glycoconjugate vaccine.
However, the proven ability of CRM197 to act as a suitable carrier
without interfering with the protective properties of the vaccine
has stood the test of time, and licensing alternative carrier
proteins will require signiﬁcant evaluation.
Coupling
Since the original identiﬁcation of CjPglB numerous orthologues
have been identiﬁed, largely among the epsilon-proteobacteria
subdivision of bacteria. Indeed, some bacteria have two PglB
paralogues.37 The quest for alternatives to CjPglB are to: (i)
broaden the range of glycans that can be coupled, (ii) have more
active enzymes with higher efﬁciency for coupling and (iii) have
PglB enzymes that recognise alternative carrier protein sequons.
For example, PglBs have been identiﬁed from two species of
Desulfovibrio that did not require the negatively charged amino
acid at position-2 and were, therefore, able to glycosylate a shorter
N-X-S/T sequon.38,39 Similarly, using PglB orthologues from the
deep-sea vent epsilon-proteobacteria demonstrated altered spe-
ciﬁcity in the OST enzymes.40
In 2011 the crystal structure of the PglB enzyme of Campylo-
bacter lari was determined, which has acted as a guide for a
directed evolution approach to modify the functional character-
isation of CjPglB orthologues, with the goal of relaxing the
acceptor-sequon speciﬁcity.41
EXTENDING THE CAPABILITIES OF PGCT
In the 18 years since its inception, glycoengineering in bacteria
using GET and PGCT has come a long way. It was originally
thought that CjPglB had an absolute requirement for the presence
of an acetamido group modiﬁcation on the reducing end sugar in
order for the glycan to be transferred. However, an exception to
this restriction was provided with the transfer of the Burkholderia
pseudomallei K96243 O-antigen repeating unit with the structure
-3-)-β-D-glucopyranose-(1–3)-α-L-6-deoxy-talopyranose-(1- to the
C. jejuni carrier protein AcrA, where talose was the reducing end
sugar.42 In order to achieve this transfer, a wecA and waaL deletion
strain was constructed (E. coli SDB1). A likely explanation as to why
this strain enabled transfer of a typically non-permissive sugar is
that, in the absence of metabolic load competition from the
enterobacterial common antigen and ligase pathways, the Und-PP
lipid carrier shunted the B. pseudomallei O-antigen to PglB for
glycosylation of the acceptor protein. Therefore, under favourable
conditions, CjPglB can transfer glycans without an acetamido
modiﬁcation on the reducing end sugar.
In 2015, Ihssen et al.43 reported a structure guided directed
evolution approach for CjPglB in order to enhance its ability to
transfer glycans that lack N-acetyl sugars. This work resulted in the
modiﬁcation of the amino acids S80R, Q287P and N311V in CjPglB.
When this modiﬁed O-Tase was introduced into Salmonella
enterica LT2 for a typhoid vaccine conjugate, transfer of the LT2
O-antigen was evident, even though the reducing end sugar is
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Fig. 2 Glycoengineering approach to the production of glycoconjugate vaccines. An E. coli cell is transformed with three plasmids to generate
the glycoconjugate protein (GP). PGCT occurs in three stages: stage 1; Glycan expression, stage 2; Carrier protein design and expression, stage
3; Coupling. The polysaccharide is synthesised on an undecaprenol pyrophosphate lipid anchor (blue/black circle) within the cytoplasm; this is
transferred to the periplasmic compartment where PglB recognises the lipid linked reducing end sugar and transfers the polysaccharide en
bloc onto an acceptor-sequon (D/E-X-N-X-S/T) on the carrier protein to produce the GP. IM, inner membrane; OM, outer membrane. This ﬁgure
is adapted from Cuccui et al.70
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galactose. More recently, the structure of PglB bound to a reactive
LLO has been reported providing more information about the
close interactions within the active site.44
A further limitation to CjPglB appears to be related to the
structure of adjacent sugars to the end group of the polysacchar-
ide being transferred. It has been reported that PglB is unable to
transfer polysaccharides where the two sugars proximal to the
lipid carrier are connected via a β-(1→ 4) linkage.45 However, in
their study dolichol, a non-native isoprene carrier, was used
instead of undecaprenol. It may be that CjPglB exhibits selectivity
toward the isoprene carrier; dolichol contains more isoprene units
and also lacks a double bond, compared to undecaprenol, which
would afford dolichol saccharides greater rotational mobility.46 If
linkage were the sole reason why some polysaccharides cannot be
transferred, then there is a potentially signiﬁcant technological
restriction, as the majority of S. pneumoniae serotypes have this β-
(1→ 4) linkage. However, there is evidence that the transfer
limitation may be more complex than just linkage. Valderrama-
Rincon et al. demonstrated utilisation of CjPglB to create
humanised glycoproteins, where the two sugars nearest the lipid
carrier are GlcNAc β1→ 4 GlcNAc.47 In their initial study
glycosylation efﬁciency was low ( < 1% protein glycosylated) but
subsequent efforts have increased efﬁciency of protein glycosyla-
tion tenfold.48
PGCT is not limited to using PglBs, and new enzymes are
continually being discovered that extend the capabilities of
biological conjugation further. In recent years, O-linked OTases,
often referred to as PglL, have been discovered and their functions
characterised, in a similar manner to the early PglB work. The PglL
family of enzymes demonstrate increased substrate promiscuity
relative to PglBs. They do not require an acetamido group
modiﬁcation at the reducing end of a polysaccharide. The greatest
challenge with this system appears to be: (i) controlling this
promiscuity by generating E. coli strains with minimal interfering
polysaccharide biosynthetic pathways, and (ii) reducing the size of
the amino acid acceptor-sequon. In elegant studies by the Wang
group, they demonstrated transfer of the O-antigen of Salmonella
paratyphi A (which has a galactose reducing end sugar) to a
modiﬁed cholera toxin B subunit by the Neisseria meningitides O-
Tase, PglL.26,27 Here, a fragment of N. meningitides PilE,
(45SAVTEYYLNHGEWPGNNTSAGVATSSEIK73) in which Ser63 was
the native glycosylation site,49 was fused to the C-terminus of the
cholera toxin B subunit. Previous studies reported that the use of
short polysaccharide chains may not induce a sufﬁcient immune
response.50–53 In a subsequent study, the group addressed this by
deleting the gene responsible for controlling the length of the
polysaccharide chain, cld. This resulted in a recombinant S.
paratyphi A O-antigen glycoconjugate with a chain length of ~20
repeats that demonstrated excellent immunogenic properties.27
Recently, it has been demonstrated that a newly identiﬁed O-
linked OST from Acinetobacter species, PglS, can couple S.
pneumoniae capsular polysaccharides with glucose as a reducing
end sugar, which could not be coupled with CjPglB.54 This paves
the way for a polyvalent vaccine produced using bioconjugation
as ~70% of serotypes have glucose at the reducing end55;
including 9/13 serotypes in the currently licensed pneumococcal
Prevnar13 glycoconjugate vaccine.
In addition to OSTases, a cytoplasmic glycosyltransferase in the
GT41 family (NGT) from Actinobacillus pleuropneumoniae, has been
demonstrated to create N-glycosidic linkages at asparagine
residues, within an NXS/T sequon with UDP-glucose as the
substrate.56–58 Much of the research with this enzyme has focused
on biochemical characterisation and its potential for vaccine
assembly is currently being explored.59
CONSIDERATIONS OF THE HOST CELL
The ability to engineer commonly used laboratory strains such as
E. coli to efﬁciently synthesise non-native sugar structures by the
recombinant expression of enzymes from different carbohydrate
biosynthesis pathways is a pre-requisite for efﬁcient product yield,
scaling up and vaccine production. It is necessary for E. coli (or
other bacterial hosts) to have the requisite biosynthetic machinery
to generate such products. Therefore, depending on a range of
factors including removing interfering pathways and streamline
expression of the cloned glycan, the degree of polymerisation for
O-antigen or capsular polysaccharides, and whether the native
sugars are present, it may be necessary to use a range of
speciﬁcally mutated and adapted E. coli strains.
Burkholderia pseudomallei
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Francisella tularensis O 
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Streptococcus 
pneumoniae serotype 4
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pneumoniae serotype 8
Glycan synthesis genes
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Fig. 3 Glycan expression technology (GET). To express foreign sugar structures in E. coli, ﬁrst the genes responsible for synthesising the glycan
must be cloned. The example here is CPS I coding locus of B. pseudomallei K96243. Expression of these genes leads to synthesis and export of
the foreign sugar attached to lipid A, in the absence of the native O-antigen from E. coli. a–d show Immunoﬂuorescence microscopy of E. coli
cells coated with the new sugar structures. Cells were probed with group or type-speciﬁc anti-glycan antibodies and Alexa Fluor 488
conjugated secondary antibody. A, unpublished; B, reproduced from Cuccui et al.70; c, d reproduced from Kay et al.66
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It is often desirable to have some of the competing glycan
production pathways from E. coli removed to reduce metabolic
load. Such mutants with major glycan structures removed are
available to the community and include the SCM strain series:
SCM360 and SCM6 (constructed by the Valvano lab), and SCM7
(constructed by the Aebi lab) from SΦ874.61 Also, CLM2423 and
CLM37 strains,22 with targeted disruption of waaL and wecA,
respectively are useful for glycoengineering. The SCM strains have
large regions of the chromosome deleted, including the entire rfb
and wca clusters, destroying O-antigen and colanic acid coding
regions. However, although this may help in terms of metabolic
streamlining, in some instances these regions may contain
pathways that form the necessary precursors for the expression
on the target glycan (e.g., some S. pneumoniae capsule serotypes,
with rhamnose biosynthesic pathways61). A more targeted
approach has been described recently, whereby the native
polysaccharide gene clusters are replaced with pathways for
recombinant glycan expression. This allows for similar glycosyla-
tion efﬁciency but higher glycoprotein yields due to enhanced
growth dynamics.62
One example of improving PGCT has been the notion that
overexpression of pglB can be harmful to the host cell. PglB is a 13-
transmembrane enzyme and it has been reported that over-
expression actually reduces total protein yield.63 This result
conﬁrms that biological conjugation is a process that requires a
balance between optimal glycosylation and overall protein yield.
This balance is likely to require ﬁne-tuning when glycan and
protein combinations are changed, as polysaccharides can place
different metabolic burdens on the host E. coli cell. We have
recently demonstrated how S. pneumoniae serotype 4 capsular
polysaccharide production within E. coli can be signiﬁcantly
enhanced by removing the function of the native wecA gene
(encoding the UDP-N-acetylglucosamine Und-PP transferase) and
replacing it with the UDP-glucose-4-epimerase encoding gene,
gnE from C. jejuni (unpublished data).
Another example of tailoring the E. coli strain for glycoconjugate
production and puriﬁcation is to reduce toxicity from co-puriﬁed
host elements such as lipid A. Removal of the myristoyl group
from lipid A (lpxM mutation) readily reduces endotoxicity of the
vaccine product with retention of protective efﬁcacy in mice.64,65
CURRENT DEVELOPMENTS OF RECOMBINANT
GLYCOCONJUGATE VACCINES
Glycoconjugate vaccines and vaccine candidates produced using
PGCT fall into three general areas of development:
Improving existing vaccines
Streptococcus pneumoniae is a globally important cause of
infectious disease, responsible for a high proportion of cases of
pneumonia, meningitis and sepsis. Although existing vaccines
based on capsular polysaccharide antigen chemically conjugated
to a protein carrier are effective, they have signiﬁcant short-
comings, including expense, limited serotype coverage, lack of
ﬂexibility in altering target serotypes, and reduction in efﬁcacy
over time due to serotype replacement. It is estimated that the
global pneumococcal vaccine market, which includes 10 and 13-
valent glycoconjugate vaccines, is £5 billion, but still a reported
estimate of nearly one million infants die each year of
pneumococcal disease where at least an equivalent is burdened
with the disease through long-term complications. The commer-
cial 10- and 13-valent vaccines largely use CRM197 as the
chemically conjugated carrier protein. To date several capsules
have been expressed in E. coli using GET66 and capsule serotype 4
has been coupled to the C. jejuni AcrA carrier protein by PGCT.67
This vaccine has been shown to protect against homologous
challenge in the murine pneumococcal infection model.67 It is
possible that PGCT could be exploited to produce vaccines
equivalent to those that are currently licenced at lower cost, or
with increased valency. However, there are limitations, including
which capsular polysaccharides can be efﬁciently expressed in
E. coli and the fact that most S. pneumoniae capsular serotypes are
incompatible with the coupling enzyme CjPglB.
An alternative approach being developed is to use conserved
S. pneumoniae proteins as carriers for capsular polysaccharide
antigens, which may provide heterologous protection against
non-vaccine capsular serotypes and improve mucosal defences by
stimulating Th17 immunity. Using this double-hit approach it has
been shown that PGCT can make S. pneumoniae protein/capsular
antigen glycoconjugates that, in murine models, induce similar
levels of anti-capsular antibody to existing vaccines, as well as
strong anti-protein antigen responses that recognise heterologous
capsular serotypes.36 Additionally, the expression of multiple
capsular polysaccharides serotypes in E. coli opens up the
possibility of glyOMVs as a vaccine alternative. With these recent
results, it is likely that GET and PGCT will collectively deliver a
broad-coverage, effective and low-cost S. pneumoniae glycocon-
jugate vaccine with novel protein/capsule combinations.
The ability to ‘graft’’ the sequon onto various parts of a protein
means that PGCT is suitable to create a new generation of
knowledge-based glycoconjugate vaccines, to maximise activation
of the adaptive immune response. A model, proposed by Avci
et al.,68 suggests that a glycoconjugate vaccine is internalised by
antigen presenting cells, and that once inside, the vaccine
undergoes degradation into shorter glycan polymers, but also
that the protein would be broken down into peptides. These short
glycopeptides are capable of binding directly to MHC class II
receptors and were presented/recognised by a speciﬁc subpopu-
lation of T cells (known as carbohydrate speciﬁc T cells or Tcarbs).
More recently, this Tcarb dependent concept was demonstrated
for other glycoconjugates including the Vi antigen of Salmonella
Typhi, the CPS of type Ib group B streptococci, and the CPS of H.
inﬂuenzae type b.69 PGCT is ideally suited to the glycosylation of
speciﬁc sites on an acceptor peptide, as a parallel to the four-
amino acid addition used in the GBSIII-OVAp study, the PglB
targeting sequence D/EXNYS/T can be grafted onto an acceptor
peptide. Thus, the potential of the technology is to reduce
vaccination costs, not only through the biological conjugation
process, but by also creating more potent antigens, with the
possibility of reducing vaccine dosage. We, and others have also
recently demonstrated that, depending on the polysaccharide,
polymerisation can be controlled when the glycan is being
heterologously expressed in the E. coli cell. Thus, in several cases
we can assemble a range of polymer lengths from short up to
lengths exhibited by the native organism. Interestingly, not all
glycoconjugates are Tcarb dependent and, it was recently shown
that, the group C polysaccharide of the N. meningitidis vaccine
appears to require a different mechanism of presentation.69
New vaccines
For many bacterial diseases, including high-threat pathogens,
there are no current protective vaccines available. To address this
unmet medical need, there has been a recent surge in the
construction of tailor made glycoconjugate vaccines against a
range of pathogens using PGCT. Examples of high-threat
pathogens include Francisella tularensis, where a single O-
antigen was coupled to Pseudomonas ExoA carrier protein and
was shown to protect in the murine infection model.70 More
recently the ExoA construct was modiﬁed with seven O-antigen
repeats using glycotags. This second generation, more heavily
glycosylated vaccine, was shown to be considerably more
protective in both the murine and rat infection models of
tularaemia.31 Similarly, O-antigen conjugate constructs have been
shown to protect against the high-threat pathogen Burkholderia
E. Kay et al.
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pseudomallei, in the murine meliodosis infection model.42 Elegant
glycoengineering studies have been used to construct a
Staphylococcus aureus capsular conjugate with ExoA that protects
against infection in a murine model.28 Some vaccines produced by
PGCT have entered clinical trials, including O-antigen conjugates
for Shigella dysenteriae type I,71 Shigella ﬂexneri 2a,72 and
uropathogenic pathogenic E. coli73 (Table 1). A wider selection
of possible glycoconjugate vaccines has recently been reviewed.1
New opportunities
Given the foreseen reduction in the costs of recombinant
glycoconjugate vaccines made using GET and PGCT, it is possible
to consider glycoconjugate vaccines for the livestock and animal
markets, where low cost is the major driving force in vaccine
development. Apart from protecting animals against disease and
the associated economic advantages, vaccines against zoonotic
pathogens will directly beneﬁt human health and reduce the use
of antibiotics in the livestock industry. Some concepts currently
being explored in our laboratory include, creating live attenuated
organisms that deliver a payload of a glycoconjugate vaccine. This
‘trojan horse’’ approach is particularly attractive as it promises to
match current manufacturing costs and storage conditions, whilst
providing protection against additional pathogens.
Biological conjugation is also being explored in the creation of
humanised glycoproteins. This process has been described as a
‘bottom up approach’’, as bacterial cells have yet to be discovered
that create the human pentasaccharide core glycan. For this
research, PglB variants have been created and tested using a
process termed GlycoSNAP, with the aim of being able to transfer
the human pentasaccharide core glycans to NXS/T.74 This also
increases the range of potential carrier proteins that can be used
with PGCT. Similarly, GlycoSCORES is a systematic platform for
glycosylation sequence characterisation and optimisation, by
rapid expression and screening, that has been used to identify
glycosylation consensus sequences in other glycosyltransferases,
including the cytoplasmic N-linked glycosylation system NGT.75
CONCLUSION AND FUTURE PERSPECTIVES
Infections caused by bacterial pathogens, especially antibiotic-
resistant ones, are an ever-increasing public health threat and
global problem. Glycoconjugate vaccines are among the most
effective means in combating such infections. To date, glycocon-
jugate vaccines have had a huge impact on global infant mortality
and morbidity. Glycoconjugate vaccine production using PGCT
has enormous potential to make a signiﬁcant impact on bacterial
disease, both in humans and animals. The proof of principle
experiments have been completed, and a number of vaccines are
now in clinical trials. The evidence is mounting that the
technology works, and further technical modiﬁcations are being
developed to improve yield, the quality of the products and the
ﬂexibility in design.
It is perhaps surprising that we still don’t fully understand why
glycoconjugates are such effective vaccines, particularly in infants.
The Kasper group have presented a plausible model where the
glycoconjugate bound to a T-cell receptor is internalised and, in
the endosome, is broken down into smaller peptides.68 Both the
peptide and polysaccharide are trimmed, allowing for binding of a
glycopeptide to major histocompatibility complex class II and
presentation of this moiety to the T cell. This model appears to
answer the long-standing question as to why co-administered
protein and sugar, which are not covalently bound, fail to induce
an optimal immune response.
Although covalent linkage is the basis of current licenced
vaccines, there are immunological models, and prototype
vaccines, being generated that are starting to indicate that there
may be alternative ways in which T cell help may be elicited. A
protein capsular matrix vaccine, where capsule is trapped in a
protein matrix, produced an equivalent immune response in mice
to a covalently linked conjugate vaccine,76 and alternative
approaches such as GMMAs77 and OMVs,10–12 where the glycan
is not covalently attached to protein, also appear to be successful
in preparing the immune system. Conjugating polysaccharide to a
lipid carrier has also been shown to provide protection in mouse
studies.78 Further studies will be required to demonstrate how
widely applicable these new approaches may be.
Given the plethora of diverse glycoconjugate vaccine candi-
dates now available through PGCT, these models can now be put
to the test. This may provide useful clues as to how current
glycoconjugate vaccines could be improved, by rationally design-
ing the protein carrier and the glycan attached to it. The more
candidates that are evaluated, the greater contribution to a true
understanding of how glycoconjugate vaccines work, and what
makes a useful fully effective protein carrier. The resulting vaccine
candidates will shed light on how the immune system responds to
carbohydrates and provide mechanistic insight that can help
guide future vaccine design. The full potential of glycoconjugate
vaccines has not yet been reached.6 New vaccines on the horizon
Table 1. Current glycoconjugate vaccines is developed using PGCT
Organism Glycan Protein
carrier
Status Manufacturer References
Streptococcus
pneumoniae
Capsule-multivalent rEPA Phase I
clinical trials
Limmatech Biologics NCT03303976a
Streptococcus
pneumoniae
Capsule-serotype 4 piuA Development Academic- UCL/LSHTM UK Reglinski et al.36
Staphylococcus aureus Capsule-Type 5 and 8 rEPA Development GlycoVaxyn Wacker et al.28
Shigella dysenteriae Capsule-Type 1 rEPA Phase I
clinical trials
Limmatech Biologics Hatz et al.71
Shigella ﬂexneri Capsule- 2a rEPA Phase I
clinical trials
Limmatech Biologics Riddle et al.72
Escherichia coli O-antigen-ExPEC serotypes 01, 02,
06, 025
rEPA Phase Ib
clinical trials
Limmatech Biologics/ J&J Huttner et al.79
Francisella tularensis O-antigen rEPA Development Government/ Academic -DSTL/ LSHTM UK Marshall et al.31
Burkholderia
pseudomallei
O-PSII AcrA Development Government/ Academic- DRDC/ University of
Alberta Canada
Garcia-Quintanilla
et al.42
PGCT-adapted from Micoli1
aClinicalTrials.gov Identiﬁer
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using PGCT include those against Groups A and B Streptococci,
Brucella, EPEC, EHEC and traveller’s diarrhoea.1
Further developments in the glycoengineering toolbox will
allow this exciting ﬁeld to continue at the forefront of scientiﬁc
discovery. Bacterial glycoengineering has now come of age; the
glycotoolbox will continue to evolve with further opportunities for
vaccinology and beyond. As carbohydrate-based vaccine formula-
tions continue to be improved, so too will their clinical potential
beyond pathogenic bacteria, into vaccines against viruses,
parasites and cancer.
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